{"success":true,"data":{"pressRelease":{"id":"159707","rtpr_id":"nGNX6T2jcq-20261002","ticker":"SPRO","exchange":"NASDAQ","all_tickers":["SPRO"],"title":"Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-10-02T20:05:00.537Z","article_body":"CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=1JCLLq_7GltKfODHgbYVJuBqtVC8EKM-bkO1xHKCXT5IhDcjNd0hnNyJEE7W_Oq1s0lF004Y_H0ixWigLYzBlh5JbG4FKOhTw-8KkSk2tsY=)\n(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines in immunology and inflammation, today\nannounced that the Compensation Committee of Spero’s Board of Directors\napproved grants, made on October 1, 2026, of an aggregate of 233,000\nrestricted stock unit awards (RSUs) and 323,000 stock options to new employees\nunder the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as\namended (2019 Inducement Plan). The stock options and RSUs are being granted\nas an inducement material to Spero’s new employees in accordance with Nasdaq\nListing Rule 5635(c)(4).\n\nThe 2019 Inducement Plan is used exclusively for the grant of equity awards to\nindividuals who were not previously employees of Spero (or following a bona\nfide period of non-employment), as a material inducement for such individuals\nentering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq\nListing Rules.\n\nThe shares underlying the options vest as to 25% on the first anniversary of\nthe employee's start date, with the remainder vesting in 36 equal monthly\ninstallments thereafter, subject to the employees' continued employment with\nSpero through the applicable vesting dates. The RSUs will vest in four equal\nannual installments beginning on the first anniversary of the employee's start\ndate, subject to the employees' continued employment with Spero through the\napplicable vesting dates. The stock options and the RSUs are subject to the\nterms and conditions of the 2019 Inducement Plan and the stock option and the\nRSU agreement covering the grant.\n\nAbout Spero Therapeutics\nSpero Therapeutics is a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines for patients with serious immune-mediated\ndiseases. The company’s lead program, SP001, is a third-generation,\nFc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related\ndisease, with potential for development in additional immunological and\ninflammatory diseases. For more information, visit www.sperotx.com\n\nInvestor Relations Contact:\nShai Biran, PhD\nSpero Therapeutics \nIR@Sperotx.com \n\n(https://www.globenewswire.com/Tracker?data=1KvujUbYxEgOhtkI68eeEcxF2CfcrmgLlGCNxYI9vdrAWWF0lNOTl7GRKOOv3mcD)\n\nMedia Inquiries: \nmedia@sperotx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/908599b7-dec6-4771-91e4-e8e60bea78e6)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6T2jcq-20261002","title":"Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"SPRO","created":"2026-10-02T20:05:00.537Z","tickers":["SPRO"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=1JCLLq_7GltKfODHgbYVJuBqtVC8EKM-bkO1xHKCXT5IhDcjNd0hnNyJEE7W_Oq1s0lF004Y_H0ixWigLYzBlh5JbG4FKOhTw-8KkSk2tsY=)\n(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines in immunology and inflammation, today\nannounced that the Compensation Committee of Spero’s Board of Directors\napproved grants, made on October 1, 2026, of an aggregate of 233,000\nrestricted stock unit awards (RSUs) and 323,000 stock options to new employees\nunder the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as\namended (2019 Inducement Plan). The stock options and RSUs are being granted\nas an inducement material to Spero’s new employees in accordance with Nasdaq\nListing Rule 5635(c)(4).\n\nThe 2019 Inducement Plan is used exclusively for the grant of equity awards to\nindividuals who were not previously employees of Spero (or following a bona\nfide period of non-employment), as a material inducement for such individuals\nentering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq\nListing Rules.\n\nThe shares underlying the options vest as to 25% on the first anniversary of\nthe employee's start date, with the remainder vesting in 36 equal monthly\ninstallments thereafter, subject to the employees' continued employment with\nSpero through the applicable vesting dates. The RSUs will vest in four equal\nannual installments beginning on the first anniversary of the employee's start\ndate, subject to the employees' continued employment with Spero through the\napplicable vesting dates. The stock options and the RSUs are subject to the\nterms and conditions of the 2019 Inducement Plan and the stock option and the\nRSU agreement covering the grant.\n\nAbout Spero Therapeutics\nSpero Therapeutics is a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines for patients with serious immune-mediated\ndiseases. The company’s lead program, SP001, is a third-generation,\nFc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related\ndisease, with potential for development in additional immunological and\ninflammatory diseases. For more information, visit www.sperotx.com\n\nInvestor Relations Contact:\nShai Biran, PhD\nSpero Therapeutics \nIR@Sperotx.com \n\n(https://www.globenewswire.com/Tracker?data=1KvujUbYxEgOhtkI68eeEcxF2CfcrmgLlGCNxYI9vdrAWWF0lNOTl7GRKOOv3mcD)\n\nMedia Inquiries: \nmedia@sperotx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/908599b7-dec6-4771-91e4-e8e60bea78e6)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-02T20:05:00.619142262Z","server_sent_at_ms":1790971500619},"received_at":"2026-10-02T20:05:00.755Z","source_url":null},"analysis":{"id":"148301","press_release_id":"159707","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Spero Therapeutics announced inducement grants of 233,000 RSUs and 323,000 stock options to new employees under its 2019 Inducement Equity Incentive Plan, made on October 1, 2026.\n\nThe grants were approved under Nasdaq Listing Rule 5635(c)(4), which covers equity awards used as a material inducement for new hires outside the standard equity plan.\n\nOptions vest 25% on the first anniversary with monthly vesting thereafter; RSUs vest in four equal annual installments. The release is routine compensation disclosure with no earnings or pipeline update.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement equity grants to new hires — no action needed."},"keyFigures":{"customDimensions":{"rsu_awards":233000,"stock_options":323000}},"namedEntities":{"people":[{"name":"Shai Biran, PhD","role":"Investor Relations Contact"}],"products":["SP001"],"companies":[{"name":"Spero Therapeutics, Inc.","ticker":"SPRO","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate Nasdaq Rule 5635(c)(4) inducement grant notice for new hires — routine equity compensation disclosure with no strategic or financial materiality."},"tickerRelevance":{"others":[],"primary":"SPRO"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-equity-grant","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Spero Therapeutics announced inducement grants of 233,000 RSUs and 323,000 stock options to new employees under its 2019 Inducement Equity Incentive Plan, made on October 1, 2026.\n\nThe grants were approved under Nasdaq Listing Rule 5635(c)(4), which covers equity awards used as a material inducement for new hires outside the standard equity plan.\n\nOptions vest 25% on the first anniversary with monthly vesting thereafter; RSUs vest in four equal annual installments. The release is routine compensation disclosure with no earnings or pipeline update.","key_figures":{"customDimensions":{"rsu_awards":233000,"stock_options":323000}},"named_entities":{"people":[{"name":"Shai Biran, PhD","role":"Investor Relations Contact"}],"products":["SP001"],"companies":[{"name":"Spero Therapeutics, Inc.","ticker":"SPRO","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T20:05:09.689Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-equity-grant","issuerAuthored":true}},"durationMs":3789,"modelName":"glm-5.3-flashx"}}